Ratings by Stifel (Dara Azar)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/24/2026 | Summit Therapeutics plc | SMMT | Maintain | Buy (N/A) |
|
Details | ||
| 7/1/2026 | Enliven Therapeutics | ELVN | Maintain | Buy (N/A) |
|
Details | ||
| 6/8/2026 | Enliven Therapeutics | ELVN | New Coverage | Buy (N/A) |
34.71 (52.95) |
52.55% | Details | |
| 6/2/2026 | Inhibrx Biosciences | INBX | Maintain | Buy (Buy) |
|
Details | ||
| 6/1/2026 | Summit Therapeutics plc | SMMT | Maintain | Buy (Buy) |
|
Details | ||
| 5/15/2026 | Inhibrx Biosciences | INBX | Maintain | Buy (N/A) |
|
Details | ||
| 4/22/2026 | Inhibrx Biosciences | INBX | Maintain | Buy (N/A) |
|
Details | ||
| 4/21/2026 | Summit Therapeutics plc | SMMT | Maintain | Buy (N/A) |
|
Details | ||
| 4/17/2026 | Inhibrx Biosciences | INBX | Maintain | Buy (Buy) |
|
Details | ||
| 4/7/2026 | Inhibrx Biosciences | INBX | New Coverage | Buy (N/A) |
63.72 (81.55) |
27.98% | Details | |
| 4/7/2026 | Summit Therapeutics plc | SMMT | New Coverage | Buy (N/A) |
18.69 (13.66) |
-26.91% | Details |
